A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice

Safinamide is an approved drug for the treatment of motor fluctuations in Parkinson's disease (PD). Scarce data are available on its use in clinical practice. A group of Spanish movement disorders specialists was convened to review the use of safinamide across different clinical scenarios that...

Descripción completa

Detalles Bibliográficos
Autores: Pagonabarraga Mora, Javier|||0000-0002-3248-704X, Arbelo, José Matías|||0000-0002-8148-8807, Grandas, Francisco, Luquin, Maria-Rosario|||0000-0002-5594-1794, Martinez-Martin, Pablo|||0000-0003-0837-5280, Rodríguez-Oroz, Mari Cruz, Valldeoriola, Francesc|||0000-0002-8680-4274, Kulisevsky, Jaime|||0000-0003-4870-1431
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:227677
Acceso en línea:https://ddd.uab.cat/record/227677
https://dx.doi.org/urn:doi:10.3390/brainsci10030176
Access Level:acceso abierto
Palabra clave:Safinamide
Efficacy
Safety
Fluctuations
Dyskinesia
RAND/UCLA appropriateness method
id ES_816a92bf4e6ecc667648aaae0ccbe5c7
oai_identifier_str oai:ddd.uab.cat:227677
network_acronym_str ES
network_name_str España
repository_id_str
spelling A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical PracticePagonabarraga Mora, Javier|||0000-0002-3248-704XArbelo, José Matías|||0000-0002-8148-8807Grandas, FranciscoLuquin, Maria-Rosario|||0000-0002-5594-1794Martinez-Martin, Pablo|||0000-0003-0837-5280Rodríguez-Oroz, Mari CruzValldeoriola, Francesc|||0000-0002-8680-4274Kulisevsky, Jaime|||0000-0003-4870-1431SafinamideEfficacySafetyFluctuationsDyskinesiaRAND/UCLA appropriateness methodSafinamide is an approved drug for the treatment of motor fluctuations in Parkinson's disease (PD). Scarce data are available on its use in clinical practice. A group of Spanish movement disorders specialists was convened to review the use of safinamide across different clinical scenarios that may guide neurologists in clinical practice. Eight specialists with recognized expertise in PD management elaborated the statements based on available evidence in the literature and on their clinical experience. The RAND/UCLA method was carried, with final conclusions accepted after a 2-round modified Delphi process. Higher level of agreement between panellists was reached for the following statements. Safinamide significantly improves mean daily OFF time without troublesome dyskinesias. Adjunctive treatment with safinamide is associated with motor improvements in patients with mid-to-late PD. The efficacy of safinamide on motor fluctuations is maintained at long-term, with no increase over time in dyskinesias severity. The clinical benefits of safinamide on pain and depression remain unclear. Safinamide presents a similar incidence of adverse events compared with placebo. The efficacy and safety of safinamide shown in the pivotal clinical trials are reproduced in clinical practice, with improvement of parkinsonian symptoms, decrease of daily OFF time, control of dyskinesias at the long term, and good tolerability and safety.Universitat Autònoma de Barcelona 22020-01-0120202020-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/227677https://dx.doi.org/urn:doi:10.3390/brainsci10030176reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2276772026-06-06T12:50:31Z
dc.title.none.fl_str_mv A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice
title A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice
spellingShingle A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice
Pagonabarraga Mora, Javier|||0000-0002-3248-704X
Safinamide
Efficacy
Safety
Fluctuations
Dyskinesia
RAND/UCLA appropriateness method
title_short A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice
title_full A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice
title_fullStr A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice
title_full_unstemmed A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice
title_sort A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice
dc.creator.none.fl_str_mv Pagonabarraga Mora, Javier|||0000-0002-3248-704X
Arbelo, José Matías|||0000-0002-8148-8807
Grandas, Francisco
Luquin, Maria-Rosario|||0000-0002-5594-1794
Martinez-Martin, Pablo|||0000-0003-0837-5280
Rodríguez-Oroz, Mari Cruz
Valldeoriola, Francesc|||0000-0002-8680-4274
Kulisevsky, Jaime|||0000-0003-4870-1431
author Pagonabarraga Mora, Javier|||0000-0002-3248-704X
author_facet Pagonabarraga Mora, Javier|||0000-0002-3248-704X
Arbelo, José Matías|||0000-0002-8148-8807
Grandas, Francisco
Luquin, Maria-Rosario|||0000-0002-5594-1794
Martinez-Martin, Pablo|||0000-0003-0837-5280
Rodríguez-Oroz, Mari Cruz
Valldeoriola, Francesc|||0000-0002-8680-4274
Kulisevsky, Jaime|||0000-0003-4870-1431
author_role author
author2 Arbelo, José Matías|||0000-0002-8148-8807
Grandas, Francisco
Luquin, Maria-Rosario|||0000-0002-5594-1794
Martinez-Martin, Pablo|||0000-0003-0837-5280
Rodríguez-Oroz, Mari Cruz
Valldeoriola, Francesc|||0000-0002-8680-4274
Kulisevsky, Jaime|||0000-0003-4870-1431
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Safinamide
Efficacy
Safety
Fluctuations
Dyskinesia
RAND/UCLA appropriateness method
topic Safinamide
Efficacy
Safety
Fluctuations
Dyskinesia
RAND/UCLA appropriateness method
description Safinamide is an approved drug for the treatment of motor fluctuations in Parkinson's disease (PD). Scarce data are available on its use in clinical practice. A group of Spanish movement disorders specialists was convened to review the use of safinamide across different clinical scenarios that may guide neurologists in clinical practice. Eight specialists with recognized expertise in PD management elaborated the statements based on available evidence in the literature and on their clinical experience. The RAND/UCLA method was carried, with final conclusions accepted after a 2-round modified Delphi process. Higher level of agreement between panellists was reached for the following statements. Safinamide significantly improves mean daily OFF time without troublesome dyskinesias. Adjunctive treatment with safinamide is associated with motor improvements in patients with mid-to-late PD. The efficacy of safinamide on motor fluctuations is maintained at long-term, with no increase over time in dyskinesias severity. The clinical benefits of safinamide on pain and depression remain unclear. Safinamide presents a similar incidence of adverse events compared with placebo. The efficacy and safety of safinamide shown in the pivotal clinical trials are reproduced in clinical practice, with improvement of parkinsonian symptoms, decrease of daily OFF time, control of dyskinesias at the long term, and good tolerability and safety.
publishDate 2020
dc.date.none.fl_str_mv 2
2020-01-01
2020
2020-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/227677
https://dx.doi.org/urn:doi:10.3390/brainsci10030176
url https://ddd.uab.cat/record/227677
https://dx.doi.org/urn:doi:10.3390/brainsci10030176
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411972165926912
score 15,300719

Similares en LA Referencia